"10.1371_journal.pone.0017963","plos one","2011-03-31T00:00:00Z","Roman H Haefeli; Michael Erb; Anja C Gemperli; Dimitri Robay; Isabelle Courdier Fruh; Corinne Anklin; Robert Dallmann; Nuri Gueven","Santhera Pharmaceuticals, Liestal, Switzerland; Biozentrum, University of Basel, Basel, Switzerland; Institut Straumann AG, Basel, Switzerland; Novartis Pharma AG, Basel, Switzerland; Institute of Pharmacology and Toxicology, University of Zürich, Zürich, Switzerland","Conceived and designed the experiments: RHH ME ACG NG. Performed the experiments: RHH ME ACG DR CA NG. Analyzed the data: RHH ME ACG DR NG. Contributed reagents/materials/analysis tools: ICF CA. Wrote the paper: RHH NG. RHH ME RD NG.","The authors have read the journal's policy and have the following conflicts: During the preparation of this manuscript, all authors were paid employees of Santhera Pharmaceuticals (Switzerland). Santhera is marketing Catena® (idebenone) for the treatment of Friedreich's Ataxia in Canada and is currently evaluating the compound in other indications in phase II and III trials. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","03","Roman H Haefeli","RHH",8,TRUE,4,6,5,2,TRUE,TRUE,TRUE,1,"7",FALSE
